Frankfurt
17.08.26 | 09:55
0,623 Euro
-3,56 % -0,023
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
| Di | Arch Biopartners Inc: Arch Biopartners to expand LSALT phase II trial | 4 | Stockwatch | ||
| Di | Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States | 975 | GlobeNewswire (Europe) | TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting... ► Artikel lesen | |
| 17.07. | Arch Biopartners Inc: Arch Biopartners hires lab for IL-32 kidney program | 1 | Stockwatch | ||
| 17.07. | Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program | 1 | GlobeNewswire (USA) | ||
| 04.06. | Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans | 1 | GlobeNewswire (USA) | ||
| 25.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 25.05.2026 | 705 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.05.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.05.2026
Aktien
1 GRS148003015 Ideal Holdings S.A.
2... ► Artikel lesen | |
| 22.05. | Arch Biopartners Inc: Arch Biopartners notes patient dosing in phase II trial | 1 | Stockwatch | ||
| 22.05. | Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial | 1 | GlobeNewswire (USA) | ||
| 30.04. | Arch Biopartners Inc: Arch Biopartners talks patient recruitment at RCH | 1 | Stockwatch | ||
| 11.04. | Arch Biopartners Inc: Arch Biopartners one-million-share private placement | 1 | Stockwatch | ||
| 02.04. | Arch Biopartners Inc: Arch Biopartners closes $600,000 private placement | 2 | Stockwatch | ||
| 02.04. | Arch Biopartners Closes Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
| 30.03. | Arch Biopartners Inc: Arch Biopartners arranges $600,000 private placement | 2 | Stockwatch | ||
| 30.03. | Arch Biopartners Arranges Non-Brokered Private Placement | 3 | GlobeNewswire (USA) | ||
| 25.03. | Arch Biopartners Inc: Arch, Royal Columbian enter clinical trial deal | 1 | Stockwatch | ||
| 24.03. | Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial | 2 | GlobeNewswire (USA) | ||
| 20.03. | Arch Biopartners Inc: Arch Biopartners begins dosing at 3rd CS-AKI trial site | 1 | Stockwatch | ||
| 20.03. | Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide | 1 | GlobeNewswire (USA) | ||
| 05.11.25 | Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia | 257 | GlobeNewswire (Europe) | TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Research Ethics Board ("REB")... ► Artikel lesen | |
| 17.09.25 | Arch Biopartners: Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) | 203 | GlobeNewswire (Europe) | Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| APOGEE THERAPEUTICS | 134,56 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | 0,00 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| AMYLYX PHARMACEUTICALS | 21,625 | 0,00 % | Mizuho raises Amylyx stock price target to $30 on higher pricing | ||
| TANGO THERAPEUTICS | 25,610 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,950 | 0,00 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| KYMERA THERAPEUTICS | 117,37 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| CLIMB BIO | 16,340 | 0,00 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,10 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,690 | 0,00 % | Wainwright reiterates Dyne Therapeutics stock rating on trial outlook | ||
| ARCUTIS BIOTHERAPEUTICS | 26,195 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,69 | 0,00 % | Kiniksa auf Wachstumskurs: ARCALYST-Umsatz steigt, Pipeline wird ausgebaut | ||
| BEAM THERAPEUTICS | 26,740 | 0,00 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy |
Das Unternehmen ARCH BIOPARTNERS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,623 Euro und damit -3,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCH BIOPARTNERS INC finden Sie auf Wallstreet Online.